Compare BWAY & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | SLDB |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.2M | 444.9M |
| IPO Year | 2019 | 2018 |
| Metric | BWAY | SLDB |
|---|---|---|
| Price | $25.45 | $6.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $26.50 | $14.70 |
| AVG Volume (30 Days) | 119.9K | ★ 1.0M |
| Earning Date | 03-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 213.09 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $49,094,000.00 | N/A |
| Revenue This Year | $330.76 | N/A |
| Revenue Next Year | $22.24 | N/A |
| P/E Ratio | $77.54 | ★ N/A |
| Revenue Growth | ★ 27.08 | N/A |
| 52 Week Low | $7.84 | $2.41 |
| 52 Week High | $25.16 | $7.37 |
| Indicator | BWAY | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 70.20 | 62.56 |
| Support Level | $22.90 | $6.35 |
| Resistance Level | $24.78 | $6.95 |
| Average True Range (ATR) | 1.23 | 0.40 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 95.76 | 80.79 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.